Clinical Lung Cancer10.1016/j.cllc.2021.12.0042022232116-121Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung CancerMarleen E. Logtenberg, Ben Tomlow, Elisabeth A. Kastelijn, Franz M.N.H. Schramel,
Lung Cancer10.1016/0169-5002(95)90721-11995132229Concurrent chemoradiotherapy followed by surgery for advanced stage III non-small cell lung cancer (NSCLC),
Lung Cancer10.1016/s0169-5002(18)30174-02018115S63-S64Service evaluation of stage III non-small cell lung cancer concurrent chemoradiotherapy treatment at Royal Cornwall Hospital Trust, TruroF. Mark,
Lung Cancer10.1016/s0169-5002(97)83929-3199718112Chemoradiotherapy for stage III non-small cell lung cancerEverett E. Vokes,
British Journal of Cancer10.1038/s41416-020-01070-62020123S110-17Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancerJohn Conibear,,,
Lung Cancer10.1016/s0169-5002(19)30236-32019127S80A retrospective analysis of lymphopenia rates during and after sequential and concurrent radical chemoradiotherapy for patients with stage III non-small cell lung cancer (NSCLC)R. Westley, L. Philipps, I. Lock, M. Ahmed, F. Mcdonald,
Lung Cancer10.1016/j.lungcan.2013.11.0172014832117-125How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?Neil Bayman, Fiona Blackhall, Paula McCloskey, Paul Taylor, Corinne Faivre-Finn,
Radiotherapy and Oncology10.1016/s0167-8140(04)80621-2200472S37121 Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer: Experience of a single institution,
Clinical Lung Cancer10.1016/j.cllc.2014.08.0052015163183-192How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III TrialHans H. Strøm, Roy M. Bremnes, Stein H. Sundstrøm, Nina Helbekkmo, Ulf Aasebø,
Lung Cancer10.1016/0169-5002(95)99004-21995123320Concurrent chemo-radiotherapy for stage III non-small cell lung cancer,